BioNotebook: Biothera, Synta, CureVac, UCSD
This article was originally published in Scrip
Executive Summary
Biothera reveals positive top-line Phase IIb data; Synta to expand Phase III study; CureVac partners with nonprofits on clinical testing; and UCSD gets $100m for stem cell research.